Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Brillian Pharma Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape features 1 pending office action. This action is handled by 1 distinct examiner, ALLEY, GENEVIEVE S, who is the sole examiner identified in the portfolio. The activity is localized in a distinct art unit, which points to a concentrated technical scope for the company's pharmaceutical applications. ALLEY, GENEVIEVE S is the busiest examiner, overseeing the busiest examiner pending action.
For a practitioner, the presence of 1 pending office action suggests a focused stage of portfolio development. Since a distinct examiner and a distinct art unit are involved, the prosecution strategy can be optimized for the specific examination environment of ALLEY, GENEVIEVE S. The fact that the busiest examiner pending action is handled by this individual means that all current USPTO interactions are centralized. This streamlined profile in the Biotechnology & Pharmaceuticals sector facilitates direct management of the company's patent assets and pharmaceutical claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618020 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | ALLEY, GENEVIEVE S | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17618020 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | ALLEY, GENEVIEVE S | 1611 | §103§112DP | Non-Final OA | — | Pending | Dec 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBrillian Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Genevieve S Alley has the most, with 1 of Brillian Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
